PolyPid Overview

  • Founded
  • 2008
Founded
  • Status
  • Public
  • Employees
  • 69
Employees
  • Stock Symbol
  • PYPD
Stock Symbol
  • Share Price
  • $9.21
  • (As of Friday Closing)

PolyPid General Information

Description

PolyPid Ltd is a clinical stage specialty pharmaceutical company engaged in research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the Company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, BonyPid-1000, BonyPid-500, PLEX, and D-PLEX are trademarks of the Company. The Company is subject to extensive regulation by the FDA, under the Federal Food, Drug, and Cosmetic Act, as well as by other federal, state, and local regulatory agencies.

Contact Information

Website
www.polypid.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Delivery
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 18 Hasivim Street
  • Post Office Box 7126
  • Petach Tikva 4959376
  • Israel
+972 000-000-0000

PolyPid Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

PolyPid Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$9.21 $9.20 $8.40 - $19.45 $173M 18.7M 30.6K -$26.53

PolyPid Financials Summary

In Thousands,
USD
TTM 31-Mar-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 127,230 139,349
Revenue 0 0 0 0
EBITDA (36,314) (6,003) 6,244
Net Income (39,687) (36,869) (6,905) 5,917
Total Assets 69,839 75,847 33,752 14,484
Total Debt 0 0 12,241 22,926
Public Fundamental Data provided by Morningstar, Inc. disclaimer

PolyPid Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore PolyPid‘s full profile, request access.

Request a free trial

PolyPid Executive Team (20)

Name Title Board Seat Contact Info
Amir Weisberg Chief Executive Officer & Board Member
Dikla Akselbrad Chief Financial Officer, Finance & Executive Vice President
Dikla Akselbrad Co-Chief Financial Officer and Co-Executive Vice President
Shaun Marcus Co-Chief Financial Officer
Shaul Mukhtar Ph.D Chief Operating Officer, Operations & Executive Vice President
You’re viewing 5 of 20 executive team members. Get the full list »

PolyPid Board Members (20)

Name Representing Role Since
Amir Weisberg PolyPid Chief Executive Officer & Board Member 000 0000
Anat Tsour Segal Xenia Venture Capital Board Member 000 0000
Arik Lukach PolyPid Board Member 000 0000
Chaim Hurvitz PolyPid Board Member 000 0000
Chaim Hurvitz Self Board Member 000 0000
You’re viewing 5 of 20 board members. Get the full list »

PolyPid Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PolyPid Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore PolyPid‘s full profile, request access.

Request a free trial